A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion

Study Identifier
APMA-OZU-01-01
CT.gov Identifier
NCT01903720
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Macular Edema
    • Study Drug
  • dexamethasone implant
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of macular edema * Best corrected visual acuity of approximately 20/400 to 20/40 in the study eye
    Exclusion Criteria:
    * Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month * Intraocular surgery, including cataract surgery, and/or laser surgery of any type within 3 months * Any active ocular infection in either eye

    Protocol Summary

    This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.

    Study Locations

    Location
    Status
    Location
    Seoul, Republic of Korea
    Status
    Not applicable